Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Hugues Talbot Clear advanced filters

  • In this single-arm phase 2 trial in patients with HR+HER2− advanced breast cancer, treatment with the HER3-targeting antibody–drug conjugate paritumab deruxtecan led to encouraging objective response rates, and comprehensive exploratory analyses indicate potential biomarkers of response.

    • Barbara Pistilli
    • Fernanda Mosele
    • Guillaume Montagnac
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 3492-3503

  • Full spectral and temporal control of light has a multitude of applications but is often limited in frequency resolution. The authors implement a scheme using a frequency shifting optical loop for optical field spectral shaping with a high degree of control and megahertz resolution

    • Côme Schnébelin
    • José Azaña
    • Hugues Guillet de Chatellus
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-11

  • Producing versatile radio-frequency chirped waveforms often requires complicated techniques. The authors use a fiber-optic frequency-shifting loop to create a low-complexity photonic chirp generator with high bandwidth and fully flexible properties for application in radar, spectroscopy, and imaging.

    • Hugues Guillet de Chatellus
    • Luis Romero Cortés
    • José Azaña
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-12

  • Trastuzumab deruxtecan, an anti-HER2–drug conjugate, exhibits the highest objective response rate in patients with HER2-overexpressing metastatic breast cancer, but clinical activity is also observed in patients with HER2-low or non-expressing tumors, potentially pointing to additional determinants of drug efficacy.

    • Fernanda Mosele
    • Elise Deluche
    • Fabrice André
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 2110-2120

  • The SARS-COV-2 pandemic has put pressure on intensive care units, so that predicting severe deterioration early is a priority. Here, the authors develop a multimodal severity score including clinical and imaging features that has significantly improved prognostic performance in two validation datasets compared to previous scores.

    • Nathalie Lassau
    • Samy Ammari
    • Michael G. B. Blum
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-11